For those that don't read posts on IFlub, here is
Post# of 72447
(Total Views: 595)
Posted On: 10/01/2021 10:18:30 AM
For those that don't read posts on IFlub, here is another excellent post by JFM that he posted this morning..... Thanks JFM!!!!
MM are using M*K/Ridgeback to hit IPIX...M*K is a mild/moderate infection therapy with 50% greater efficacy than Placebo(Remdesivir)???
What is the real efficacy???
Brilacidin is Moderate to Severe infection ... days away...IMO we are looking for 85% greater efficacy vs Remdesivir/Placebo...
No evidence M*K would be effective in Moderate/Severe hospitalized patients ...
ps... Ridgeback's other problem has not been raised by MEDIA YET!
Remember: "Raymond Schinazi, an Emory University chemist who has extensively studied the active ingredient in EIDD-2801 but has no connection to DRIVE, notes that his former pharmaceutical company, Pharmasset, abandoned it in 2003 after discovering its mutagenic properties. Schinazi says the small chemical tweaks made to increase the ingredient’s bioavailability and transform it into EIDD-2801 are unlikely to change its mutagenicity. “Thank goodness someone is raising the red flag,” about EIDD-2801, Schinazi says.
Quote:
“You don’t develop a drug that’s mutagenic. Period.
”
MM are using M*K/Ridgeback to hit IPIX...M*K is a mild/moderate infection therapy with 50% greater efficacy than Placebo(Remdesivir)???
What is the real efficacy???
Brilacidin is Moderate to Severe infection ... days away...IMO we are looking for 85% greater efficacy vs Remdesivir/Placebo...
No evidence M*K would be effective in Moderate/Severe hospitalized patients ...
ps... Ridgeback's other problem has not been raised by MEDIA YET!
Remember: "Raymond Schinazi, an Emory University chemist who has extensively studied the active ingredient in EIDD-2801 but has no connection to DRIVE, notes that his former pharmaceutical company, Pharmasset, abandoned it in 2003 after discovering its mutagenic properties. Schinazi says the small chemical tweaks made to increase the ingredient’s bioavailability and transform it into EIDD-2801 are unlikely to change its mutagenicity. “Thank goodness someone is raising the red flag,” about EIDD-2801, Schinazi says.
Quote:
“You don’t develop a drug that’s mutagenic. Period.
”
(6)
(0)